Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

p applicant Almirall

Almirall/Lilly lebrikizumab offers potential long-term management of atopic dermatitis

pharmaphorum

SEPTEMBER 16, 2022

Having been in development by Almirall and Eli Lilly and Company for moderate to severe AD, recent findings from a phase 3 trial for the first time have shown year-long (52-week) management of symptoms, in comparison with short-term 16-week maintenance of previous trials. The 16-week data was made public in March of this year.

Dermatology

Dermatology Trials Drugs Development

FDA Approves Klisyri (tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp

The Pharma Data

DECEMBER 15, 2020

Klisyri is the first FDA approved branded proprietary product for Athenex and will be launched in partnership with Almirall in the U.S. We are excited to partner with Almirall to bring this first-in-class microtubule inhibitor to patients with actinic keratosis in the US.”. Athenex has partnered with Almirall (Almirall, S.A.,

FDA Approval

FDA Approval Development Production Marketing

Almirall/Lilly lebrikizumab offers potential long-term management of atopic dermatitis

FDA Approves Klisyri (tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp

Stay Connected